Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Prospective Clinical Study Evaluating the Safety and Efficacy of Propranolol Combined With Tislelizumab Plus Gemcitabine/Cisplatin as Neoadjuvant Therapy for cT1-4aN1-3M0 Bladder Urothelial Carcinoma

NCT07353294 is registered in ClinicalTrials.gov with Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University as lead sponsor.

NCT NCT07353294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07353294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Prospective Clinical Study Evaluating the Safety and Efficacy of Propranolol Combined With Tislelizumab Plus Gemcitabine/Cisplatin as Neoadjuvant Therapy for cT1-4aN1-3M0 Bladder Urothelial Carcinoma
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
January 1, 2026
Completion date
June 30, 2029
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder urothelial carcinoma, lymph node metastasis